# US 2025/0144247 A1 · Formulations to enhance the delivery of gene therapy vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144247 A1
- Document ID: US20250144247A1
- Status: Published application
- Kind: A1
- Application number: 18/936,764
- Filed: 2024-11-04
- Published: 2025-05-08
- Earliest claimed: 2023-11-02
- Assignees: University of Iowa Research Foundation
- Applicants: University of Iowa Research Foundation
- Inventors: Ashley Cooney; Patrick Sinn; Paul B. McCray, JR.
- Web page: https://patentgrep.com/patent/US20250144247A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C12N 15/86: Viral vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Method to enhance the delivery of one or more gene therapy vectors to cells comprising contacting said cells with a hypertonic solution before. after or simultaneously with said one or more gene therapy vectors.

## Claims

### Claim 1

A method to enhance the delivery of one or more gene therapy vectors to cells comprising contacting said cells with a hypertonic solution before, after or simultaneously with said one or more gene therapy vectors as compared to a control.

### Claim 2

A method to enhance the delivery of one or more gene therapy vectors to a subject in need thereof comprising administering to said subject a hypertonic solution before, after or simultaneously with said one or more gene therapy vectors as compared to a control.

### Claim 3

A method to restore cystic fibrosis transmembrane conductance regulator (CFTR) function to cells of subjects with cystic fibrosis comprising contacting said cells with a hypertonic solution before, after or simultaneously with said one or more gene therapy vectors.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cells comprise epithelial cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cells are pulmonary epithelial cells.

### Claim 6 (depends on 2)

The method of claim 2, wherein the subject as a disease or disorder of a hollow organ.

### Claim 7 (depends on 6)

The method of claim 6, wherein the hollow organ comprises respiratory tract, lung, sinus, intestinal tract, mouth, esophagus, stomach, bladder, gallbladder, reproductive tract or heart.

### Claim 8 (depends on 6)

The method of claim 6, wherein the disease or disorder is a genetic disease or disorder.

### Claim 9 (depends on 6)

The method of claim 6, wherein the disease or disorder comprises cystic fibrosis, primary ciliary dyskinesia (PCD), surfactant deficiencies or underlying causes of interstitial lung disease, atopic lung disease, asthma, bronchiectasis, bronchiolitis obliterans, cystic lung diseases, Alpha-1 antitrypsin (AAT) deficiency, alveolar diseases in alveolar type 1 or 2 cells (e.g., alveolar type 2 deficiencies (ABCA3 Deficiency, Surfactant Protein B Deficiency)), lung cancer, Crohn's, ulcerative colitis, colon cancer, Lynch syndrome, familial adenomatous polyposis (FAP), inflammatory bowel disease, oral cancer, achalasia, GERD, esophageal cancer, Barrett's syndrome, stomach cancer, bladder cancer, bladder exstrophy, incontinence, Giltelman syndrome, gallstones, cardiomyopathies, channelopathies, heart disease, inherited heart conditions, hypertrophic cardiomyopathy (HCM), idiopathic or familial dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), restrictive cardiomyopathy, Carney complex, cancer, pancreatic diseases, kidney diseases, vascular diseases, bone diseases, spleen diseases, ear diseases, skin diseases, and/or blood diseases.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cancer comprises a sarcoma, carcinoma, lung cancer, adenocarcinoma, adenocarcinoma of the lung, squamous carcinoma, squamous carcinoma of the lung, malignant mixed mullerian tumor, head and/or neck cancer, breast cancer, esophageal cancer, mouth cancer, tongue cancer, gum cancer, skin cancer, muscle cancer, heart cancer, liver cancer, bronchial cancer, cartilage cancer, bone cancer, stomach cancer, prostate cancer, testicular cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine cancer, pancreatic cancer, colon cancer, rectal cancer, colorectal, gastric cancer, kidney cancer, bladder cancer, spleen cancer, thymus cancer, thyroid cancer, brain cancer, neuronal cancer, mesothelioma, gall bladder cancer, ocular cancer, joint cancer, glioblastoma, neuroblastoma, hereditary non-polyposis cancer (HNPC), and/or colitis-associated cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the gene therapy vector is a viral vector.

### Claim 12 (depends on 11)

The method of claim 11, wherein the viral vector comprises adenovirus, adeno-associated virus (AAV), lentivirus, retrovirus, bocavirus, oncolytic vector, and/or virus like particles (VLPs).

### Claim 13 (depends on 1)

The method of claim 1, wherein the gene therapy vector is a plasmid, viral nucleic acid, RNA, peptide, protein, phage nucleic acid, phage, cosmid, artificial chromosome, or via transfer of genetic material in cells or carriers such as cationic liposomes or nanoparticles.

### Claim 14 (depends on 1)

The method of claim 1, wherein the hypertonic solution is a hypertonic salt solution.

### Claim 15 (depends on 14)

The method of claim 14, wherein the hypertonic salt solution comprises one or more monovalent salts.

### Claim 16 (depends on 15)

The method of claim 15, wherein the one or more monovalent salts comprise sodium chloride (NaCl), potassium chloride (KCl), and/or lithium chloride (LiCl).

### Claim 17 (depends on 14)

The method of claim 14, wherein the hypertonic salt solution comprises one or more divalent salts.

### Claim 18 (depends on 17)

The method of claim 17, wherein the one or more divalent salts comprise calcium chloride (CaCl2), magnesium sulfate (MgSO4), magnesium chloride (MgCl2), zinc cholirde (ZnCl2), zinc sulfate (ZnSO4), calcium lactate (C6H10CaO6), ferrous sulfate (FeSO4), calcium glycerylphosphate and/or ferrous chloride (FeCl2) or charged sugar (e.g., N-methyl-D-gluconate) with ionic strength.

### Claim 19 (depends on 14)

The method of claim 14, wherein the salt concentration is from about 1% to about 8%.

### Claim 20 (depends on 19)

The method of claim 19, wherein the salt concentration is from about 3.5% to about 7%.

### Claim 21 (depends on 19)

The method of claim 19, wherein the salt concentration is from about 3.5% to about 4.5% NaCl.

### Claim 22

The method of 2, wherein the hypertonic solution is administered by inhalation, instillation, topical delivery, or injection.

### Claim 23 (depends on 22)

The method of claim 22, wherein the injection is an intra-tumoral injection.
